Global Search

Search articles, concepts, and chapters

Section III · Management

Chapter 27: Management of the Glaucoma Patient

Shields' Textbook of Glaucoma, 6th edition

Showing 1–20 of 5,670 articles

8.
Basic Science

Transplantation of human trabecular meshwork stem cells induces cell proliferation and intraocular pressure reduction in a cell loss model of glaucoma.

Iswarya Radhakrishnan, Haribalaganesh Ravinarayanan, Senthilkumari Srinivasan et al.

Graefes Arch Clin Exp OphthalmolMar 2026

This study found transplanted trabecular meshwork stem cells reduced intraocular pressure and increased cell proliferation in a glaucoma model, suggesting a potential therapy for outflow pathway dysfunction.

10.
Randomized Controlled Trial

Design and Baseline Characteristics of Participants in the Clarifying the Optimal Application of Selective Laser Trabeculoplasty (SLT) Therapy (COAST) Trial 1.

Realini Tony, Balasubramani G K, Kenkre Tanya et al.

J GlaucomaMar 2026

The COAST trial compares standard versus low-energy SLT for new glaucoma/OHT. The abstract details the study design and baseline patient characteristics, showing a representative sample, which will clarify optimal SLT use for long-term glaucoma management.

1 / 284

Chloramphenicol, Latanoprost, and Hypromellose with Dextran were the most dispensed ophthalmic agents in New Zealand between 2012 and 2021.

EpidemiologyCohortnationwide population-level retrospective studyn=10,941,081 dispensing events

Glaucoma medications were predominantly dispensed to older individuals in New Zealand between 2012 and 2021.

EpidemiologyCohortnationwide population-level retrospective studyn=10,941,081 dispensing events

A large language model (LLM) achieved an accuracy of 0.91 (sensitivity, 0.96; specificity, 0.91) for identifying medication non-adherence in clinical notes.

DiagnosisCross-sectionalPerformance Evaluationn=1125 glaucoma-related encounters

The total cost for prostaglandin analogue (PGA) prescribing over 5 years (2019-2024) in England was £166 million for 21.9 million prescriptions.

EpidemiologyCross-sectionalObservational studyn=21.9 million prescriptions across all Clinical Commissioning Groups (CCGs) in England

A broad trend towards generic prostaglandin analogue (PGA) prescribing was identified in England between 2019 and 2024.

EpidemiologyCross-sectionalObservational studyn=21.9 million prescriptions across all Clinical Commissioning Groups (CCGs) in England

Branded and preservative-free prostaglandin analogue (PGA) prescribing, in preference to a generic equivalent, resulted in an additional cost of approximately £54 million in England between 2019 and 2024.

Comparative EffectivenessCross-sectionalObservational studyn=21.9 million prescriptions across all Clinical Commissioning Groups (CCGs) in England

For patients undergoing pars plana vitrectomy (PPV) with 14% C₃F₈ gas tamponade, air travel (2,400 m cabin) was predicted to be safe after day 35.

PrognosisBasic ScienceComputational Modelingn=Not applicable

For patients undergoing pars plana vitrectomy (PPV) with SF₆ gas tamponade, air travel (2,400 m cabin) was predicted to be safe after day 22.

PrognosisBasic ScienceComputational Modelingn=Not applicable

For patients undergoing pars plana vitrectomy (PPV) with C₂F₆ gas tamponade, air travel (2,400 m cabin) was predicted to be safe after day 22.

PrognosisBasic ScienceComputational Modelingn=Not applicable

For patients undergoing pars plana vitrectomy (PPV) with 100% air tamponade, air travel (2,400 m cabin) was predicted to be safe after day 13.

PrognosisBasic ScienceComputational Modelingn=Not applicable

Micropulse trans-scleral cyclophotocoagulation (MP-TSCPC) significantly reduced mean intraocular pressure (IOP) by 10% (from 25.08±5.06 mm Hg to 22.56±4.89 mm Hg, p=0.005) in patients with open-angle glaucoma and ocular hypertension 6 months post-treatment.

TreatmentCohortObservational Studyn=31 patients

No serious ocular or systemic adverse events occurred during the 52-week follow-up period in patients with advanced non-syndromic retinitis pigmentosa treated with a single intravitreal injection of UGX-201.

TreatmentCase seriesOpen-label, non-randomized, single-center trialn=9 patients with advanced non-syndromic RP